Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 183

The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.

Design and baseline characteristics of participants in the Researching cardiovascular Events with a Weekly IN cretin in Diabetes ( REWIND ) trial on the cardiovascular effects of dulaglutide

Open access
Gerstein, Hertzel C., Colhoun, Helen M., Dagenais, Gilles R., Diaz, Rafael, Lakshmanan, Mark, Pais, Prem, Probstfield, Jeffrey, Riddle, Matthew C., Rydén, Lars, Xavier, Denis, Atisso, Charles M., Avezum, Alvaro, Basile, Jan, Chung, Namsik, Conget, Ignacio, Cushman, William C., Franek, Edward, Hancu, Nicolae, Hanefeld, Markolf, Holt, Shaun, Jansky, Petr, Keltai, Matyas, Lanas, Fernando, Leiter, Lawrence A., Lopez‐Jaramillo, Patricio, Cardona‐Munoz, Ernesto G., Pirags, Valdis, Pogosova, Nana, Raubenheimer, Peter J., Shaw, Jonathan, Sheu, Wayne H‐H., Temelkova‐Kurktschiev, Theodora, on behalf of the REWIND Trial Investigators · 2018 · Diabetes, Obesity and Metabolism

Abstract

The aim was to determine the effects of dulaglutide, a synthetic once‐weekly, injectable human glucagon‐like peptide 1 analogue that lowers blood glucose, body weight, appetite and blood pressure, on cardiovascular outcomes. People with type 2 diabetes, aged ≥50 years, with glycated haemoglobin ( HbA1c ) ≤9.5%, and either a previous cardiovascular event, evidence of cardiovascular disease or ≥2 cardiovascular risk factors were randomly allocated to a weekly subcutaneous injection of either dulaglutide (1.5 mg) or placebo and followed within the ongoing R esearching cardiovascular E vents with a W eekly IN cretin in D iabetes ( REWIND ) trial every 3 to 6 months. The primary cardiovascular outcome is the first occurrence of the composite of cardiovascular death or non‐fatal myocardial infarction or non‐fatal stroke. Secondary outcomes include each component of the primary composite cardiovascular outcome, a composite clinical microvascular outcome comprising retinal or renal disease, hospitalization for unstable angina, heart failure requiring hospitalization or an urgent heart failure visit, and all‐cause mortality. Follow‐up will continue until the accrual of 1200 confirmed primary outcomes. Recruitment of 9901 participants (mean age 66 years, 46% women) occurred in 370 sites located in 24 countries over a period of 2 years. The mean duration of diabetes was 10 years, mean baseline HbA1c was 7.3%, and 31% had prior cardiovascular disease. The REWIND trial's international scope, high proportion of women, high proportion of people without prior cardiovascular disease and inclusion of participants whose mean baseline HbA1c was 7.3% suggests that its cardiovascular and safety findings will be directly relevant to the typical middle‐aged patient seen in general practice throughout the world.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/dom.13028

Cites

21 of 21 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

1 retracted

Show all 21 references

Cited by

See all 183

Metadata

Authors
Gerstein, H. C., Colhoun, H. M., Dagenais, G. R., Diaz, R., Lakshmanan, M., Pais, P., Probstfield, J., Riddle, M. C., Rydén, L., Xavier, D., Atisso, C. M., Avezum, A., Basile, J., Chung, N., Conget, I., Cushman, W. C., Franek, E., Hancu, N., Hanefeld, M., Holt, S., Jansky, P., Keltai, M., Lanas, F., Leiter, L. A., Lopez‐Jaramillo, P., Cardona‐Munoz, E. G., Pirags, V., Pogosova, N., Raubenheimer, P. J., Shaw, J., Sheu, W. H., Temelkova‐Kurktschiev, T., & on behalf of the REWIND Trial Investigators
Venue
Diabetes, Obesity and Metabolism
Publisher
Wiley
Published
2017-07-14
Volume
20
Issue
1
Pages
42-49
ISSN
  • 1462-8902 (ISSN-L)
  • 1463-1326
OpenAlex
W2621101635
Cited by
183
References
21
FWCI
21.34
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Design and baseline characteristics of participants in the Researching cardiovascular Events with a Weekly IN cretin in Diabetes ( REWIND ) trial on the cardiovascular effects of dulaglutide. https://app.cochat.ai/papers/10.1111/dom.13028
The paper
Gerstein, H. C., Colhoun, H. M., Dagenais, G. R., Diaz, R., Lakshmanan, M., Pais, P., Probstfield, J., Riddle, M. C., Rydén, L., Xavier, D., Atisso, C. M., Avezum, A., Basile, J., Chung, N., Conget, I., Cushman, W. C., Franek, E., Hancu, N., Hanefeld, M., . . . on behalf of the REWIND Trial Investigators. (2018). Design and baseline characteristics of participants in the Researching cardiovascular Events with a Weekly IN cretin in Diabetes ( REWIND ) trial on the cardiovascular effects of dulaglutide. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.13028

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.